SecBot SecBot
EFFECT ·Filed Apr 7, 2026

PLRX

PLIANT THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC9999999995-26-001103
IPO/offering going effective
Actionable Insight • Neutral

Monitor for future prospectus supplements or 8-K filings indicating an actual drawdown under the shelf or ATM program, which could lead to near-term stock dilution. The $81M market cap makes even modest issuances potentially impactful.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.31
T+0 close · Apr 7, 2026 · via day close
Latest settled
−10.69%
T+60 · $1.17
Vs SPY
−23.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $1.31entry
  2. T+1 · 7mo ago +3.82%α +1.28% · $1.36
  3. T+5 · 7mo ago −0.76%α −6.09% · $1.30
  4. T+20 · 7mo ago −9.16%α −18.94% · $1.19
  5. T+60 · 5mo ago −10.69%α −23.96% · $1.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) offering program, has become effective. The company can now sell securities from time to time over the next three years, creating potential for future dilution.

Key Facts

  • Shelf registration (Form S-3) has become effective, allowing Pliant Therapeutics to raise up to $300 million in capital over the next three years.
  • Of the $300 million, $50 million is designated for an at-the-market (ATM) offering program with Leerink Partners LLC.
  • Securities offered may include common stock, preferred stock, debt, units, and warrants, with specific terms disclosed in future prospectus supplements.
  • The effectiveness allows the company to access capital markets opportunistically, but no immediate offering has been announced.

Financial Impact

Up to $300,000,000 in potential future dilution, with $50,000,000 available immediately under the ATM program

dilutionequity

Risk Factors

  • Future equity issuances could dilute existing shareholders
  • ATM program may be used during periods of low stock price, exacerbating downside pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001103
Document: 9999999995-26-001103-index.html9999999995-26-001103
Document: 9999999995-26-001103.txt9999999995-26-001103

Track record

8 reports on PLRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
  2. Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
  3. May 11, 202627w ago 8-K Neutral 4/10 No price data
  4. May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
  5. Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
  6. Apr 7, 202632w ago EFFECT Neutral 4/10 Viewing Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
  7. Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
  8. Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026